Switch to:
Also traded in: Brazil, Chile, Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.08
CVS's Cash-to-Debt is ranked lower than
96% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.12 vs. CVS: 0.08 )
Ranked among companies with meaningful Cash-to-Debt only.
CVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.14 Max: N/A
Current: 0.08
Equity-to-Asset 0.37
CVS's Equity-to-Asset is ranked higher than
57% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.38 vs. CVS: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
CVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.51 Max: 0.67
Current: 0.37
0.37
0.67
Interest Coverage 9.50
CVS's Interest Coverage is ranked higher than
50% of the 22 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.59 vs. CVS: 9.50 )
Ranked among companies with meaningful Interest Coverage only.
CVS' s Interest Coverage Range Over the Past 10 Years
Min: 9.5  Med: 11.43 Max: 15.55
Current: 9.5
9.5
15.55
Piotroski F-Score: 5
Altman Z-Score: 3.68
Beneish M-Score: -2.79
WACC vs ROIC
5.05%
10.14%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 5.57
CVS's Operating Margin % is ranked higher than
65% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 5.07 vs. CVS: 5.57 )
Ranked among companies with meaningful Operating Margin % only.
CVS' s Operating Margin % Range Over the Past 10 Years
Min: 5.57  Med: 6.3 Max: 6.91
Current: 5.57
5.57
6.91
Net Margin % 2.86
CVS's Net Margin % is ranked higher than
57% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.91 vs. CVS: 2.86 )
Ranked among companies with meaningful Net Margin % only.
CVS' s Net Margin % Range Over the Past 10 Years
Min: 2.86  Med: 3.44 Max: 3.76
Current: 2.86
2.86
3.76
ROE % 14.42
CVS's ROE % is ranked higher than
62% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.02 vs. CVS: 14.42 )
Ranked among companies with meaningful ROE % only.
CVS' s ROE % Range Over the Past 10 Years
Min: 9.14  Med: 11.33 Max: 14.42
Current: 14.42
9.14
14.42
ROA % 5.49
CVS's ROA % is ranked higher than
70% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.98 vs. CVS: 5.49 )
Ranked among companies with meaningful ROA % only.
CVS' s ROA % Range Over the Past 10 Years
Min: 5.46  Med: 5.97 Max: 7
Current: 5.49
5.46
7
ROC (Joel Greenblatt) % 69.72
CVS's ROC (Joel Greenblatt) % is ranked lower than
63% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 77.30 vs. CVS: 69.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 41.72  Med: 49.64 Max: 69.72
Current: 69.72
41.72
69.72
3-Year Revenue Growth Rate 16.70
CVS's 3-Year Revenue Growth Rate is ranked higher than
75% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.60 vs. CVS: 16.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CVS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -13.3  Med: 12.1 Max: 16.7
Current: 16.7
-13.3
16.7
3-Year EBITDA Growth Rate 11.80
CVS's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 11.60 vs. CVS: 11.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -29.4  Med: 10.8 Max: 43.7
Current: 11.8
-29.4
43.7
3-Year EPS without NRI Growth Rate 9.40
CVS's 3-Year EPS without NRI Growth Rate is ranked higher than
56% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.30 vs. CVS: 9.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.3  Med: 14.6 Max: 112.8
Current: 9.4
-48.3
112.8
GuruFocus has detected 1 Warning Sign with CVS Health Corp $CVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CVS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CVS Guru Trades in Q2 2016

Jerome Dodson 234,000 sh (New)
Ray Dalio 149,700 sh (New)
John Buckingham 43,573 sh (New)
Louis Moore Bacon 2,679 sh (New)
Paul Tudor Jones 33,167 sh (New)
Jim Simons 3,842,105 sh (+1869.25%)
Joel Greenblatt 652,002 sh (+196.03%)
George Soros 41,175 sh (+49.67%)
Robert Olstein 91,000 sh (+42.19%)
RS Investment Management 897,935 sh (+13.27%)
Murray Stahl 3,397 sh (+9.94%)
First Pacific Advisors 114,190 sh (+7.58%)
Pioneer Investments 5,751,921 sh (+7.25%)
Richard Pzena 529,884 sh (+0.23%)
Tom Gayner 247,000 sh (unchged)
Jeff Auxier 52,349 sh (unchged)
Mairs and Power 3,069 sh (unchged)
Westport Asset Management 192,090 sh (unchged)
Dodge & Cox Sold Out
Steven Cohen Sold Out
PRIMECAP Management 3,527,170 sh (-0.61%)
Manning & Napier Advisors, Inc 86,530 sh (-0.64%)
Charles de Vaulx 753,827 sh (-3.20%)
Mario Gabelli 1,139,978 sh (-4.11%)
Scott Black 17,206 sh (-5.20%)
Ruane Cunniff 14,856 sh (-7.04%)
Ken Fisher 129,783 sh (-8.81%)
NWQ Managers 607,584 sh (-14.13%)
Jeremy Grantham 1,825,963 sh (-21.26%)
» More
Q3 2016

CVS Guru Trades in Q3 2016

David Dreman 9,185 sh (New)
Barrow, Hanley, Mewhinney & Strauss 9,100,036 sh (New)
Steven Cohen 82,162 sh (New)
John Paulson 122,200 sh (New)
Eaton Vance Worldwide Health Sciences Fund 228,705 sh (New)
NWQ Managers 933,958 sh (+53.72%)
Scott Black 23,496 sh (+36.56%)
Robert Olstein 108,000 sh (+18.68%)
First Pacific Advisors 131,530 sh (+15.19%)
Jerome Dodson 256,000 sh (+9.40%)
Ken Fisher 132,741 sh (+2.28%)
Manning & Napier Advisors, Inc 87,010 sh (+0.55%)
Richard Pzena 529,858 sh (unchged)
Tom Gayner 247,000 sh (unchged)
George Soros 689,500 sh (unchged)
Ray Dalio Sold Out
Louis Moore Bacon Sold Out
George Soros Sold Out
Jeff Auxier 52,199 sh (-0.29%)
PRIMECAP Management 3,492,690 sh (-0.98%)
John Buckingham 42,964 sh (-1.40%)
Pioneer Investments 5,533,119 sh (-3.80%)
Mairs and Power 2,949 sh (-3.91%)
Murray Stahl 3,197 sh (-5.89%)
Mario Gabelli 1,065,457 sh (-6.54%)
Charles de Vaulx 703,490 sh (-6.68%)
Ruane Cunniff 13,801 sh (-7.10%)
Signature Select Canadian Fund 58,903 sh (-15.92%)
Joel Greenblatt 440,659 sh (-32.41%)
Jeremy Grantham 1,144,482 sh (-37.32%)
Jim Simons 940,005 sh (-75.53%)
Paul Tudor Jones 6,831 sh (-79.40%)
» More
Q4 2016

CVS Guru Trades in Q4 2016

Arnold Van Den Berg 69,740 sh (New)
Richard Snow 3,995 sh (New)
Ray Dalio 109,013 sh (New)
Wallace Weitz 121,162 sh (New)
John Rogers 33,499 sh (New)
Paul Tudor Jones 28,945 sh (+323.73%)
Joel Greenblatt 1,055,841 sh (+139.61%)
Manning & Napier Advisors, Inc 190,110 sh (+118.49%)
Barrow, Hanley, Mewhinney & Strauss 18,280,528 sh (+100.88%)
Charles de Vaulx 1,384,235 sh (+96.77%)
NWQ Managers 1,352,559 sh (+44.82%)
Pioneer Investments 7,679,466 sh (+38.79%)
Steven Cohen 112,900 sh (+37.41%)
Robert Olstein 140,000 sh (+29.63%)
First Pacific Advisors 161,800 sh (+23.01%)
Jeff Auxier 62,049 sh (+18.87%)
John Buckingham 45,261 sh (+5.35%)
Scott Black 24,241 sh (+3.17%)
Ken Fisher 134,917 sh (+1.64%)
Richard Pzena 533,748 sh (+0.73%)
Mario Gabelli 1,071,617 sh (+0.58%)
Tom Gayner 248,000 sh (+0.40%)
John Paulson Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Jeremy Grantham 1,140,718 sh (-0.33%)
Mairs and Power 2,879 sh (-2.37%)
PRIMECAP Management 3,409,100 sh (-2.39%)
Ruane Cunniff 13,401 sh (-2.90%)
David Dreman 8,061 sh (-12.24%)
Murray Stahl 2,767 sh (-13.45%)
Jim Simons 724,505 sh (-22.93%)
Jerome Dodson 186,000 sh (-27.34%)
» More
Q1 2017

CVS Guru Trades in Q1 2017

Charles Brandes 94,271 sh (New)
Richard Snow 288,876 sh (+7130.94%)
John Rogers 115,681 sh (+245.33%)
Paul Tudor Jones 59,741 sh (+106.39%)
Jim Simons 1,414,005 sh (+95.17%)
Ken Fisher 263,189 sh (+95.07%)
Steven Cohen 210,612 sh (+86.55%)
David Dreman 13,849 sh (+71.80%)
Ray Dalio 161,883 sh (+48.50%)
Jeff Auxier 67,049 sh (+8.06%)
Tom Gayner 264,000 sh (+6.45%)
Mairs and Power 3,034 sh (+5.38%)
Pioneer Investments 8,033,087 sh (+4.60%)
John Buckingham 46,844 sh (+3.50%)
Joel Greenblatt 1,082,388 sh (+2.51%)
Mario Gabelli 1,092,787 sh (+1.98%)
First Pacific Advisors 163,580 sh (+1.10%)
Scott Black 24,455 sh (+0.88%)
Wallace Weitz 122,123 sh (+0.79%)
Richard Pzena 534,035 sh (+0.05%)
Murray Stahl 2,767 sh (unchged)
Steven Cohen 1,154,300 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
PRIMECAP Management 3,391,470 sh (-0.52%)
Arnold Van Den Berg 68,655 sh (-1.56%)
Jeremy Grantham 1,103,290 sh (-3.28%)
Barrow, Hanley, Mewhinney & Strauss 17,400,999 sh (-4.81%)
Ruane Cunniff 12,701 sh (-5.22%)
Robert Olstein 121,925 sh (-12.91%)
NWQ Managers 1,014,208 sh (-25.02%)
Manning & Napier Advisors, Inc 141,680 sh (-25.47%)
Jerome Dodson 106,000 sh (-43.01%)
» More
» Details

Insider Trades

Latest Guru Trades with CVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Plans » Health Care Plans    NAICS: 621399    SIC: 8099
Compare:NYSE:AET, NYSE:ANTX, NYSE:CI, NAS:ESRX, NYSE:HUM, NYSE:CNC, NYSE:WCG, NYSE:MOH, OTCPK:QULRY, NAS:MGLN, NYSE:UAM, NAS:HIIQ, OTCPK:WCUI, OTCPK:OPRX, NAS:CNXR, NYSE:UNH » details
Traded in other countries:CVSH34.Brazil, CVS.Chile, CVS.Germany, CVS.Mexico,
Headquarter Location:USA
CVS Health Corp iis an integrated pharmacy health care provider. The Company has three segments: Pharmacy Services, Retail Pharmacy and Corporate.

CVS Health combines one of the largest retail pharmacy chains in the United States with one of the largest pharmacy benefit managers. The company processes approximately 1.3 billion prescriptions per year and operates more than 10,000 retail pharmacies across the U.S.

Guru Investment Theses on CVS Health Corp

Weitz Funds Comments on CVS Health - Jan 26, 2017

CVS Health (NYSE:CVS) operates a nationwide network of nearly 10,000 retail pharmacies, the nation’s second largest pharmacy benefits manager (PBM) in Caremark, and sizeable specialty and long-term care pharmacy platforms. This is the fund’s second go around with CVS, having last owned it back in 2013. CVS’ stock has been under pressure for most of the last 18 months after peaking during the summer of 2015. After nearly five years of consistent market share gains, the Caremark PBM suffered several client losses over the course of 2016. In addition, CVS also announced that its retail pharmacies would no longer be part of several important networks in 2017. These lost volumes will likely result in no earnings per share growth this year. These near-term negatives drove the stock down to a price that we found attractive. While management will need to navigate several risks over the course of the next couple of years, we believe CVS’ stock price provides an attractive valuation in the mid-$70s.



  • From Weitz Investment Management's Value Fund 4th quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

Mario Gabelli Comments on CVS Health Corp - Nov 02, 2016

CVS Health Corp. (NYSE:CVS) (2.3%) (CVS – $88.99 – NYSE) is the leading pharmacy and pharmacy benefits manager in the country, with over $150 billion in annual revenue. The stock declined in the quarter due to the significant political scrutiny around drug pricing. Efforts to regulate and control drug pricing could have an indirect impact on CVS’s revenues and earnings. However, we believe the company is a low cost provider who already works aggressively to improve health through the dispensing of low cost generic drugs, coordination of care, and efforts to improve adherence by patients.



From Mario Gabelli (Trades, Portfolio)'s Equity Income Fund 3rd quarter 2016 commentary.

Check out Mario Gabelli latest stock trades

Mario Gabelli Comments on CVS Health Corp - Feb 05, 2016

CVS Health Corp. (2.4%) (CVS – $97.77 – NYSE)(NYSE:CVS) is the leading pharmacy and pharmacy benefits manager in the country, with over $150 billion in annual revenue. The company’s recent acquisitions of institutional pharmacy Omnicare and the pharmacies inside Target stores should add $0.15 to earnings in 2016 and further CVS’s dominance across the pharmacy channel. Same store sales should improve in 2016 now that the company has annualized its decision to stop selling tobacco, and that decision has helped them win over $11 billion in net new business for its pharmacy benefits management (PBM) division.

From Mario Gabelli (Trades, Portfolio)'s GAMCO Equity Income Fund fourth quarter 2015 commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about CVS Health Corp

David Dreman Buys JPMorgan, Kroger, Reynolds Guru's largest 1st-quarter purchases
David Dreman (Trades, Portfolio) is the founder and chairman of Dreman Value Management LLC and also serves as the firm's chief investment officer. During the first quarter the guru bought shares in the following stocks. Read more...
NWQ Managers Sells Pfizer, Viacom, Edison The firm's largest 1st-quarter sales
NWQ Managers (Trades, Portfolio) is a value-oriented money management firm with several funds products and more than $54 billion under management. During the first quarter the guru sold shares in the following stocks: Read more...
Charles Brandes Invests in Health Care in 1st Quarter Guru buys AstraZeneca, CVS, Gilead Sciences, others
Charles Brandes (Trades, Portfolio)’ Brandes Investment Partners gained 49 new holdings during the quarter. Among the purchases were several health care stocks. His three largest new health care holdings are AstraZeneca PLC (NYSE:AZN), CVS Health Corp. (NYSE:CVS) and Gilead Sciences Inc. (NASDAQ:GILD). Read more...
Weitz Funds Comments on CVS Health Guru stock highlight
CVS Health (NYSE:CVS) operates a nationwide network of nearly 10,000 retail pharmacies, the nation’s second largest pharmacy benefits manager (PBM) in Caremark, and sizeable specialty and long-term care pharmacy platforms. This is the fund’s second go around with CVS, having last owned it back in 2013. CVS’ stock has been under pressure for most of the last 18 months after peaking during the summer of 2015. After nearly five years of consistent market share gains, the Caremark PBM suffered several client losses over the course of 2016. In addition, CVS also announced that its retail pharmacies would no longer be part of several important networks in 2017. These lost volumes will likely result in no earnings per share growth this year. These near-term negatives drove the stock down to a price that we found attractive. While management will need to navigate several risks over the course of the next couple of years, we believe CVS’ stock price provides an attractive valuation in the mid-$70s. Read more...
Does the Increase in Volatility Signal a Dangerous Market Environment? Anxiety typically leads to knee-jerk reactions and excessive trading in their portfolios
Over the last several weeks stock price volatility has increased significantly above norms. All of a sudden it is not uncommon to see stock prices moving 5%, 10% or more in a single trading day. Interestingly, this volatility is occurring both to the upside and the downside. Common sense would suggest that the intrinsic value of a business cannot change by those orders of magnitude from one day to the next. Logic dictates that the market is either inaccurately pricing the stocks now or it was incorrectly pricing them the day before. Read more...
Robert Olstein Continues to Buy eBay, Walt Disney Stocks the investor bought for the past 2 quarters
Robert Olstein (Trades, Portfolio) is the chairman and chief investment officer of the Olstein Financial Alert Fund. In both the second and third quarters the guru bought shares in the following stocks: Read more...
Mario Gabelli Comments on CVS Health Corp Guru stock highlight
CVS Health Corp. (NYSE:CVS) (2.3%) (CVS – $88.99 – NYSE) is the leading pharmacy and pharmacy benefits manager in the country, with over $150 billion in annual revenue. The stock declined in the quarter due to the significant political scrutiny around drug pricing. Efforts to regulate and control drug pricing could have an indirect impact on CVS’s revenues and earnings. However, we believe the company is a low cost provider who already works aggressively to improve health through the dispensing of low cost generic drugs, coordination of care, and efforts to improve adherence by patients. Read more...
Jim Simons Ups Stake in CVS Health Company is largest health care provider in US
During the second quarter, guru Jim Simons (Trades, Portfolio), the founder of the hedge fund Renaissance Technologies, added to his stake in CVS Health Corp. (CVS) by adding an additional 3,647,000 shares of the company to his portfolio. Simons now owns 3,842,105 shares of CVS Health Corp. Read more...
Ray Dalio's 5 Biggest 2nd-Quarter New Stock Buys Dalio bought Johnson & Johnson, CVS and more
Ray Dalio (Trades, Portfolio) manages the $150 billion Westport, Connecticut-based hedge fund Bridgewater Associates, the largest hedge fund firm in the world. The equity portfolio at Bridgewater has a total value of only $7.98 billion. According to filings disclosed Thursday, Dalio added 139 new positions to it in the second quarter. Read more...

Ratios

vs
industry
vs
history
PE Ratio 16.01
CVS's PE Ratio is ranked higher than
70% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 20.35 vs. CVS: 16.01 )
Ranked among companies with meaningful PE Ratio only.
CVS' s PE Ratio Range Over the Past 10 Years
Min: 10.58  Med: 17.67 Max: 27.17
Current: 16.01
10.58
27.17
Forward PE Ratio 12.95
CVS's Forward PE Ratio is ranked higher than
72% of the 36 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.62 vs. CVS: 12.95 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 15.97
CVS's PE Ratio without NRI is ranked higher than
70% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 21.38 vs. CVS: 15.97 )
Ranked among companies with meaningful PE Ratio without NRI only.
CVS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.62  Med: 17.61 Max: 27.17
Current: 15.97
10.62
27.17
Price-to-Owner-Earnings 9.48
CVS's Price-to-Owner-Earnings is ranked higher than
50% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 11.58 vs. CVS: 9.48 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CVS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.07  Med: 20.26 Max: 60.62
Current: 9.48
9.07
60.62
PB Ratio 2.34
CVS's PB Ratio is ranked higher than
70% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.55 vs. CVS: 2.34 )
Ranked among companies with meaningful PB Ratio only.
CVS' s PB Ratio Range Over the Past 10 Years
Min: 1.01  Med: 1.79 Max: 3.37
Current: 2.34
1.01
3.37
PS Ratio 0.45
CVS's PS Ratio is ranked higher than
70% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.57 vs. CVS: 0.45 )
Ranked among companies with meaningful PS Ratio only.
CVS' s PS Ratio Range Over the Past 10 Years
Min: 0.4  Med: 0.59 Max: 0.88
Current: 0.45
0.4
0.88
Price-to-Free-Cash-Flow 8.93
CVS's Price-to-Free-Cash-Flow is ranked higher than
63% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 11.11 vs. CVS: 8.93 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CVS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.86  Med: 20.56 Max: 105.34
Current: 8.93
8.86
105.34
Price-to-Operating-Cash-Flow 7.26
CVS's Price-to-Operating-Cash-Flow is ranked higher than
76% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.41 vs. CVS: 7.26 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CVS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.72  Med: 12.66 Max: 19.92
Current: 7.26
6.72
19.92
EV-to-EBIT 11.06
CVS's EV-to-EBIT is ranked higher than
53% of the 43 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.77 vs. CVS: 11.06 )
Ranked among companies with meaningful EV-to-EBIT only.
CVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.6  Med: 11.3 Max: 20.4
Current: 11.06
7.6
20.4
EV-to-EBITDA 8.74
CVS's EV-to-EBITDA is ranked lower than
53% of the 45 Companies
in the Global Health Care Plans industry.

( Industry Median: 8.48 vs. CVS: 8.74 )
Ranked among companies with meaningful EV-to-EBITDA only.
CVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.2  Med: 9.1 Max: 16
Current: 8.74
6.2
16
PEG Ratio 1.12
CVS's PEG Ratio is ranked higher than
71% of the 14 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.87 vs. CVS: 1.12 )
Ranked among companies with meaningful PEG Ratio only.
CVS' s PEG Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.29 Max: 2.34
Current: 1.12
0.57
2.34
Shiller PE Ratio 22.19
CVS's Shiller PE Ratio is ranked higher than
69% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 25.26 vs. CVS: 22.19 )
Ranked among companies with meaningful Shiller PE Ratio only.
CVS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.19  Med: 25.99 Max: 39.08
Current: 22.19
17.19
39.08
Current Ratio 1.08
CVS's Current Ratio is ranked lower than
53% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.21 vs. CVS: 1.08 )
Ranked among companies with meaningful Current Ratio only.
CVS' s Current Ratio Range Over the Past 10 Years
Min: 1.05  Med: 1.53 Max: 2.64
Current: 1.08
1.05
2.64
Quick Ratio 0.56
CVS's Quick Ratio is ranked lower than
84% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.15 vs. CVS: 0.56 )
Ranked among companies with meaningful Quick Ratio only.
CVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 0.51 Max: 0.93
Current: 0.56
0.2
0.93
Days Inventory 34.77
CVS's Days Inventory is ranked lower than
71% of the 7 Companies
in the Global Health Care Plans industry.

( Industry Median: 5.72 vs. CVS: 34.77 )
Ranked among companies with meaningful Days Inventory only.
CVS' s Days Inventory Range Over the Past 10 Years
Min: 34.77  Med: 41.44 Max: 50.81
Current: 34.77
34.77
50.81
Days Sales Outstanding 24.73
CVS's Days Sales Outstanding is ranked higher than
50% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 25.01 vs. CVS: 24.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
CVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 18.77  Med: 22.19 Max: 28.31
Current: 24.73
18.77
28.31
Days Payable 17.85
CVS's Days Payable is ranked lower than
67% of the 12 Companies
in the Global Health Care Plans industry.

( Industry Median: 42.29 vs. CVS: 17.85 )
Ranked among companies with meaningful Days Payable only.
CVS' s Days Payable Range Over the Past 10 Years
Min: 16.69  Med: 19.59 Max: 21.78
Current: 17.85
16.69
21.78

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.42
CVS's Dividend Yield % is ranked higher than
77% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.29 vs. CVS: 2.42 )
Ranked among companies with meaningful Dividend Yield % only.
CVS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.42  Med: 1.16 Max: 2.44
Current: 2.42
0.42
2.44
Dividend Payout Ratio 0.37
CVS's Dividend Payout Ratio is ranked lower than
69% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.33 vs. CVS: 0.37 )
Ranked among companies with meaningful Dividend Payout Ratio only.
CVS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.2 Max: 0.37
Current: 0.37
0.11
0.37
3-Year Dividend Growth Rate 23.60
CVS's 3-Year Dividend Growth Rate is ranked higher than
75% of the 8 Companies
in the Global Health Care Plans industry.

( Industry Median: 7.70 vs. CVS: 23.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
CVS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -33.8  Med: 8 Max: 37
Current: 23.6
-33.8
37
Forward Dividend Yield % 2.63
CVS's Forward Dividend Yield % is ranked higher than
76% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.52 vs. CVS: 2.63 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 8.28
CVS's 5-Year Yield-on-Cost % is ranked higher than
79% of the 34 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.08 vs. CVS: 8.28 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CVS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.44  Med: 3.97 Max: 8.35
Current: 8.28
1.44
8.35
3-Year Average Share Buyback Ratio 3.50
CVS's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.00 vs. CVS: 3.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.9  Med: -0.4 Max: 4.7
Current: 3.5
-22.9
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.72
CVS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
75% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.01 vs. CVS: 0.72 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CVS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.67  Med: 1.39 Max: 26.44
Current: 0.72
0.67
26.44
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.99
CVS's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
82% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.39 vs. CVS: 0.99 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.77
CVS's Price-to-Median-PS-Value is ranked higher than
67% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.91 vs. CVS: 0.77 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 0.91 Max: 2.52
Current: 0.77
0.43
2.52
Price-to-Peter-Lynch-Fair-Value 1.22
CVS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
64% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.50 vs. CVS: 1.22 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CVS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.48 Max: 6.55
Current: 1.22
0.64
6.55
Earnings Yield (Greenblatt) % 9.05
CVS's Earnings Yield (Greenblatt) % is ranked higher than
52% of the 42 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.29 vs. CVS: 9.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.9  Med: 8.8 Max: 13.2
Current: 9.05
4.9
13.2
Forward Rate of Return (Yacktman) % 19.94
CVS's Forward Rate of Return (Yacktman) % is ranked higher than
67% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 17.81 vs. CVS: 19.94 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CVS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 11.8  Med: 18.1 Max: 24.2
Current: 19.94
11.8
24.2

More Statistics

Revenue (TTM) (Mil) $178,825
EPS (TTM) $ 4.79
Beta0.62
Short Percentage of Float2.38%
52-Week Range $69.30 - 98.67
Shares Outstanding (Mil)1,035.79

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 184,447 195,331 204,892
EPS ($) 5.75 6.31 6.76
EPS without NRI ($) 5.75 6.31 6.76
EPS Growth Rate
(Future 3Y To 5Y Estimate)
14.69%
Dividends per Share ($) 1.94 2.19 2.90
» More Articles for CVS

Headlines

Articles On GuruFocus.com
David Dreman Buys JPMorgan, Kroger, Reynolds May 26 2017 
Attorney General Brnovich, Rep. Carter Join CVS Health to Announce Availability of Naloxone at All C May 23 2017 
NWQ Managers Sells Pfizer, Viacom, Edison May 22 2017 
CVS Pharmacy Launches Long Live Skin Campaign to Increase Awareness Around Sun Safety and Skin Healt May 15 2017 
CVS Health To Present At The UBS Global Healthcare Conference May 12 2017 
Charles Brandes Invests in Health Care in 1st Quarter May 11 2017 
CVS Health Stockholders Elect Former SEC Chairman Mary L. Schapiro as New Director at Annual Meeting May 10 2017 
CVS Health Corporate Social Responsibility Activities Address Important National and Local Health Ca May 10 2017 
Earnings Overreaction Gives Investors a Buying Opportunity May 04 2017 
CVS Health Offering Hepatitis A Vaccine to Hawaii Residents Following Recall of Contaminated Fish May 03 2017 

More From Other Websites
Behind the War Between Health Insurers and Pharmacy Benefit Managers May 26 2017
CVS's Omnicare to pay $23 million to resolve U.S. kickback case May 26 2017
Is CVS Health's Dividend Safe? May 25 2017
Tax Reforms and Spending Cuts to Balance Trump’s Budget Plan May 25 2017
3 Healthcare Stocks for Savvy Investors May 24 2017
A Closer Look at CVS Health's Dividend Potential May 23 2017
Attorney General Brnovich, Rep. Carter Join CVS Health to Announce Availability of Naloxone at All... May 23 2017
Why Amazon Gives CVS Health Corporation Shareholders Something to Worry About May 21 2017
Could Amazon Steamroller These Pharmacy Stocks? May 19 2017
ETFs with exposure to CVS Health Corp. : May 19, 2017 May 19 2017
LB Commercial Trust 1998-C4 -- Moody's Upgrades One Class, Affirms Two Classes and Downgrades One... May 19 2017
Evaluating Amazon's Chances in the Pharma Industry May 18 2017
CVS Health Corp. :CVS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017 May 18 2017
Amazon Faces Tough Fight Against Walgreens And CVS If It Enters Pharmacy Business May 18 2017
Amazon is breaking into the pharmacy market May 17 2017
Stocks fall as the latest Trump scandal rattles Wall Street May 17 2017
CVS Health Corp. breached its 50 day moving average in a Bearish Manner : CVS-US : May 17, 2017 May 17 2017
Why Your Pharmacy May Be Texting You May 16 2017
CVS's Omnicare to pay $8 million to settle U.S. probe May 16 2017
20 Large Retailers Besides J.C. Penney Are Closing Waves of Stores May 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)